NIR-I Dye-Based Probe: A New Window for Bimodal Tumor Theranostics.

Area of Science:

• Biomedical imaging
• Nanotechnology
• Cancer diagnostics

Background:

• Near-infrared (NIR) bioimaging, particularly NIR-I fluorescence imaging (650-950 nm), offers high quantum yield and biocompatibility for tumor diagnosis.
• Current NIR-I probes face limitations in penetration depth, driving the development of advanced imaging solutions.
• Bimodal probes integrate multiple imaging modalities to overcome individual technique drawbacks.

Purpose of the Study:

• To review the application of NIR-I fluorescent dye-contained bimodal probes, focusing on nanoprobes.
• To highlight the synergistic imaging capabilities of these bimodal nanoprobes.
• To emphasize the role of NIR-I fluorescence-based bimodal probes in cancer theranostics.

Main Methods:

• Literature review of recent advancements in NIR-I fluorescence imaging probes.
• Focus on bimodal probes incorporating NIR-I fluorescent dyes.
• Emphasis on nanoprobe designs and their synergistic imaging potential.

Main Results:

• Bimodal nanoprobes enable synergistic imaging by combining strengths of different modalities.
• These probes enhance penetration depth and diagnostic accuracy in tumor imaging.
• NIR-I fluorescence-based bimodal probes show promise for integrated cancer diagnosis and therapy (theranostics).

Conclusions:

• NIR-I fluorescence-based bimodal nanoprobes represent a significant advancement in cancer theranostics.
• These probes offer improved imaging depth and synergistic capabilities over single-modality agents.
• Further development in this area holds great potential for clinical cancer management.